沙美特罗替卡松联合布地奈德混悬液治疗慢性阻塞性肺疾病患者57例回顾性分析

Retrospective analysis of 57 cases of COPD patients treated with salmeterol fluticasone combined with budesonide suspension

目的回顾性分析沙美特罗替卡松与布地奈德混悬液联合对慢性阻塞性肺疾病(COPD)患者的疗效。方法回顾性选取2013年2月至2016年4月我院COPD患者113例,依据治疗方式不同分组,对照组56例予以沙美特罗替卡松治疗,研究组57例在对照组基础上加用布地奈德混悬液治疗,统计比较2组疗效、不良反应发生率,分析对比治疗前、治疗3个月后2组氧分压(PaO2)、二氧化碳分压(PaCO2)、酸碱度(pH)、用力肺活量(FVC)、第1秒用力呼气容积(FEV1)、FEV1占预计值百分比(FEV1%)及血清白细胞介素-6(IL-6)、IL-8及肿瘤坏死因子-α(TNF-α)水平。结果研究组总有效率96%高于对照组84%,差异有统计学意义(P<0.05);研究组治疗3个月后FVC、FEV1、FEV1%高于对照组,差异有统计学意义(P<0.05);研究组治疗3个月后血清IL-6、IL-8、TNF-α水平低于对照组,差异有统计学意义(P<0.05);研究组治疗3个月后PaO2、pH高于对照组,PaCO2低于对照组,差异有统计学意义(P<0.05);研究组不良反应总发生率11%与对照组9%比较差异无统计学意义(P>0.05)。结论 COPD患者联合采用沙美特罗替卡松与布地奈德混悬液治疗效果显著,可显著改善其动脉血气及肺功能,降低其炎症因子水平,且安全性较高。

Objective To investigate the efficacy of salmeterol fluticasone combined with budesonide suspension in the treatment of chronic obstructive pulmonary disease（COPD）.Methods A total of 113 patients with COPD in our hospital from February 2013 to April 2016 were retrospectively selected and grouped according to the treatment methods.56 patients in the control group were treated with salmeterol fluticasone and 57 patients in the study group were treated with budesonide suspension on the basis of the control group.The effects and the incidence of adverse reactions of the 2 groups were statistically compared.The partial pressure of oxygen（PaO2）,partial pressure of carbon dioxide（PaCO2）and pH（pH）,forced vital capacity（FVC）,forced expiratory volume in one second（FEV1）,the percentage of FEV1 accounting for estimated value（FEV1%）and levels of interleukin-6（IL-6）,IL-8 and tumor necrosis factor-α（TNF-α）before treatment and 3 months after treatment of two groups were analyzed and compared.Results The total effective rate of the study group（96.49%）was higher than that of the control group（83.93%）,and the difference was statistically significant（P〈0.05）.After 3 months of treatment in the study group,FVC,FEV1 and FEV1% were higher than those of the control group,and the difference was statistically significant（P〈0.05）.The levels of serum IL-6,IL-8 and TNF-αin the study group were lower than those of the control group after 3 months of treatment,and the difference was statistically significant（P〈0.05）.After 3 months of treatment,the PaO2 and pH in the study group were higher than those in the control group,and the PaCO2 was lower than that in the control group.The difference was statistically significant（P〈0.05）.There were insignificant differences in the incidence of adverse reactions between the study group（10.53%）and the control group（8.93%）（P〈0.05）.Conclusion The efficacy of salmeterol fluticasone combined with budesonide suspension in the treatment of COPD patients is significant.It can significantly improve the arterial blood gas and lung function,reduce the levels of inflammatory factors and it has high safety.